Legend Biotech (NASDAQ:LEGN – Get Rating) had its price objective lifted by investment analysts at Barclays from $53.00 to $65.00 in a research report issued to clients and investors on Wednesday, The Fly reports. Barclays‘s target price would suggest a potential upside of 19.86% from the company’s current price.
A number of other brokerages also recently issued reports on LEGN. Evercore ISI started coverage on Legend Biotech in a research report on Tuesday, November 1st. They set an “outperform” rating for the company. UBS Group started coverage on Legend Biotech in a research report on Tuesday, December 6th. They set a “buy” rating and a $66.00 price target for the company. Piper Sandler lifted their price target on Legend Biotech from $72.00 to $78.00 and gave the company an “overweight” rating in a research report on Tuesday, December 20th. Guggenheim initiated coverage on Legend Biotech in a research report on Monday, October 31st. They set a “neutral” rating for the company. Finally, JPMorgan Chase & Co. raised their price objective on Legend Biotech from $61.00 to $65.00 and gave the company an “overweight” rating in a report on Tuesday, December 6th. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $70.14.
Legend Biotech Stock Up 0.5 %
Shares of NASDAQ LEGN opened at $54.23 on Wednesday. Legend Biotech has a 52 week low of $30.75 and a 52 week high of $57.72. The business has a 50-day simple moving average of $51.16 and a two-hundred day simple moving average of $47.95. The company has a market cap of $8.90 billion, a P/E ratio of -45.57 and a beta of -0.13.
Hedge Funds Weigh In On Legend Biotech
About Legend Biotech
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma.
- Get a free copy of the StockNews.com research report on Legend Biotech (LEGN)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab’s First U.S. Launch Send Stock Into Stratosphere?
- 3 Retail Stocks Ringing the Register in 2023
Receive News & Ratings for Legend Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Legend Biotech and related companies with MarketBeat.com's FREE daily email newsletter.